Q Biomed Announces Addition Of Multi-Million Dollar Asset Value With Equity Stake In Maniin Research Inc.
NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce receipt of a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma.
Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in...
Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior...
NEW YORK, May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy and value proposition for its stakeholders and shareholders.
NEW YORK, March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.
NEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Injections under a recently inked supply contract between Q BioMed, isoSolutions Marketing and Management (our Canadian distribution partner) and Chinese radiopharmaceutical company, Chengdu Syncor Pharmaceutical Co. Ltd. The agreement is the first of what is expected to be a high-growth named patient opportunity to supply Strontium89 in the Chinese market. Chengdu Syncor is an A-list radiopharmaceuticals supplier founded by Cadillac (United States) in 1999, devoted to providing high-quality radionuclide products to its customers throughout China. The Chinese market is currently demanding 12,000 doses a year (growing 10% a year) from 2 local government run manufacturers. This order represents a small fraction of that opportunity.
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines strategic directions and goals for 2022.
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a condition caused by viral infections in the lungs including COVID-19.
Q Biomed, a commercial stage biotech company, announced that it has recently entered into an exclusive license agreement with Clionix, a reputable distributor in Europe and the Middle East.